ALXN News and Press, Alexion Pharmaceuticals Inc. From 04/19/21

Merger activity increased last week with six new deals announced. $50 billion worth of deals announced in a single week. Thermo Fisher Scientific to acquire PPD Inc. For further details see: Merger Arbitrage Mondays - Microsoft's Acquisition Of Nuance Offers A 5% Spread ...

Both S&P 500 and Nasdaq 100 stocks may be successfully included in portfolios managed with momentum strategies. The set of 78 stocks that belong to both the S&P 500 and Nasdaq 100 perform better than the sets of either index. We compare the performance of portfolios with 5...

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded today at $164.40, eclipsing its 52-week high. This new high was reached on below average trading volume as 866,000 shares traded hands, while the average 30-day volume is approximately 2.3 million shares. Alexion Pharmaceuticals...

AstraZeneca's (AZN) $39B acquisition of Alexion Pharmaceuticals (ALXN) has cleared U.S. Federal Trade Commission review.The deal is expected to close in Q3 subject to shareholder approval next month.The acquisition would give AstraZeneca a leg-up in the rare disease space given Alex...

Genworth Financial finally terminates its deal with China Oceanwide. Tribune Publishing Company receives a revised, non-binding proposal from Newslight. Leaf Group to be acquired by Graham Holdings Company. For further details see: Merger Arbitrage Mondays - Leaf Group A...

Because long-term economic prospects look promising, buying the current dip in fundamentally sound stocks could be a smart move. Qualcomm (QCOM), Vertex Pharmaceuticals (VRTX), and Alexion Pharmaceuticals (ALXN) are stocks that saw a considerable decline in the first quarter, but we think are...

Declining SPAC IPOs could indicate the SPAC bubble may have run its course. Brookfield Asset Management agrees to acquire Brookfield Property Partners after increasing its bid by 10%. Aggregate deal value in a highly competitive M&A space approaches $600 billion in Q1 202...

Investors are gradually shifting their focus away from “stay-at-home” growth stocks in favor of potential post-pandemic winners that are currently undervalued. Alexion Pharmaceuticals, Inc. (ALXN), Orange, S.A. (ORAN), Molina Healthcare, Inc. (MOH), and Albertsons Companies, Inc...

Dicerna Pharmaceuticals’ lead RNAi candidate (nedosiran) is scheduled to read out top-line data from its pivotal trial in mid-2021, with an NDA filing anticipated shortly thereafter. The company’s GalXC development platform has attracted five collaborations and more than...

Full phase 3 data for Apellis Pharmaceuticals' (APLS) paroxysmal nocturnal hemoglobinuria (PNH) drug candidate pegcetacoplan indicates it is superior to Alexion Pharmaceuticals' (ALXN) Soliris (eculizumab).The data was published in The New England Journal of Medicine.Full results from the PEG...